Parnell Pharmaceutical Holdings announced on Wednesday that sales in the last half of 2014 jumped 29% year over year to 3.7 million Australian dollars ($2.9 million). The company's net loss narrowed from AUS $5.1 million ($4 million) to AUS $2.9 million ($2.3 million).
Another company has spotted an opportunity in animal health. Petaluma, CA-based Oculus Innovative Sciences announced Thursday that it has launched an animal health unit and 6 new products for the treatment of wounds, skin and eyes. The medicines are branded MicrocynAH, and the company will introduce two additional members of the product line for farm animals soon.
Bayer Healthcare said it plans to sell its animal health production facility in St. Joseph, MO, and some of the products manufactured at the plant.
POPULAR COMMENT THREADS
Aratana Therapeutics has broken free of the red tape that has been hampering the launch of AT-004, its drug to treat B-cell lymphoma in dogs, which was fully approved by the USDA in early January. The company announced late Tuesday that it has terminated a licensing agreement with Eli Lilly's Elanco.
Fast-food giant McDonald's announced Wednesday that it will phase out all chicken raised with antibiotics used in human healthcare within the next two years. The policy is part of the company's new Global Vision for Antimicrobial Stewardship in Food Animals, according to a statement from the company.
A new study shows that cats with naturally occurring Niemann-Pick type C--which is nearly identical to the human form of the disease--are greatly helped by the active ingredient in the odor-fighting household spray Febreze.
Shares of generic drug maker Akorn ($AKRX) shot up 14% late last week to $55.86, after the company announced on Thursday strong preliminary 2014 results and expectations of 2015 year-over-year revenue growth of 47% and earnings-per-share growth of 62%.
A lawsuit filed by an angry dog owner against Nestle Purina PetCare alleges that the company's popular dog food, Beneful, has sparked more than 3,000 online complaints claiming that the product has sickened their dogs.
Dogs with spontaneously occurring, highly aggressive brain tumors such as glioblastoma multiforme have proven to be highly accurate models of human brain cancer. So when the owners of a 12-year-old mixed-breed dog with glioblastoma showed up at the Virginia-Maryland Regional College of Veterinary Medicine having exhausted all other treatment options, they agreed to try an experimental technology called nonthermal irreversible electroporation.
From Our Sister Sites
Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.
Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.